SAGE Pharmaceuticals Products

Sage Therapeutics Stock Soars

Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial instability. Learn more on SAGE stock here.

Hosted on MSN · 4d

Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid

Key Takeaways Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.

Business Insider · 4d

BofA moves to No Rating on Sage Therapeutics after Biogen bid

BofA is moving to No Rating on Sage Therapeutics (SAGE) after the company announced it has received an unsolicited, nonbinding acquisition

Zacks.com on MSN · 3d

Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?

Sage Therapeutics, Inc. (SAGE) shares soared 35.1% in the last trading session to close at $7.50. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $10.53 Consensus Target Price from Analysts

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) have been assigned a consensus rating of “Hold” from the ...

Hosted on MSN1d

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

CNN1y

SAGE Therapeutics, Inc.

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ...

bovnews4d

Sage Therapeutics (SAGE) Makes Bold Moves: What’s in Store for Investors?

Sage Therapeutics, Inc. (Nasdaq: SAGE) saw its stock price soar by an impressive 33.87%, reaching $7.43 during Monday’s premarket trading session. The surge came on the heels of the company’s ...

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?

Sage Therapeutics reviews Biogen's $7.22 per share acquisition proposal amid ongoing restructuring and focus on Zurzuvae for postpartum depression.

SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial

In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The ...

bovnews3d

SAGE Therapeutics Inc (SAGE) Stock: Understanding Its Underlying Value

RBC Capital Mkts has recently raised SAGE Therapeutics Inc (SAGE) stock to Sector Perform rating, as announced on November 21, 2024, according to Finviz. Earlier, on October 10, 2024, Raymond James ...

Benzinga.com1mon

Where Sage Therapeutics Stands With Analysts

Sage Therapeutics Inc is a clinical-stage biopharmaceutical ... receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults ...

Analysts Offer Insights on Healthcare Companies: Halozyme (HALO) and SAGE Therapeutics (SAGE)

Analysts fell to the sidelines weighing in on Halozyme (HALO – Research Report) and SAGE Therapeutics (SAGE – Research Report) with neutral ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results